-
公开(公告)号：US20230248729A1
公开(公告)日：2023-08-10
申请号：US18137610
申请日：2023-04-21
Applicant: AMGEN INC.
Inventor： Haby HENARY , James Russell LIPFORD , Victor J. CEE
IPC: A61K31/519 , A61P35/00 , A61K31/53 , A61K31/5375
CPC classification number: A61K31/519 , A61P35/00 , A61K31/53 , A61K31/5375
Abstract: Provided herein are methods of administering a KRAS G12C inhibitor to a cancer subject.
-
公开(公告)号：US20240091230A1
公开(公告)日：2024-03-21
申请号：US18270581
申请日：2022-01-07
Applicant: AMGEN INC.
Inventor： Agnes L. ANG , Haby HENARY , Gataree NGARMCHAMNANRITH
IPC: A61K31/519 , A61P35/00
CPC classification number: A61K31/519 , A61P35/00
Abstract: The present disclosure provides uses for a KRASG12C inhibitor, such as the compound of Formula I (AMG 510, sotorasib) in treating cancers, such as non-small cell lung cancer, in subjects with certain characteristics.
-
公开(公告)号：US20240408089A1
公开(公告)日：2024-12-12
申请号：US18422704
申请日：2024-01-25
Applicant: Amgen Inc.
Inventor： Haby HENARY , James Russell LIPFORD , Victor J. CEE
IPC: A61K31/505 , A61K9/00 , A61K31/53 , A61K31/5355 , A61K39/00 , A61P35/00
Abstract: Provided herein are methods of administering a KRAS G12C inhibitor to a cancer subject.
-
公开(公告)号：US20220323446A1
公开(公告)日：2022-10-13
申请号：US17696758
申请日：2022-03-16
Applicant: Amgen Inc.
Inventor： Gregory FRIBERG , Haby HENARY , Brett E. HOUK , Omar A. MATHER , Gataree NGARMCHAMNANRITH , Sandeep DUTTA
IPC: A61K31/519 , A61K31/573 , A61K33/00 , A61K33/10 , A61K33/08 , A61K31/4439 , A61K31/426 , A61K31/341 , A61K31/4164 , A61K31/4453 , A61K31/4545 , A61K31/675 , A61K31/513 , A61K31/4166 , A61K31/496 , A61K31/435 , A61K31/495 , A61K31/536 , A61K31/517 , A61K31/439 , A61K31/7048 , A61K31/445 , A61K31/506 , A61K31/4985 , A61K31/58 , A61K31/40 , A61K31/522 , A61K31/5513 , A61K31/167 , A61K31/635 , A61K31/337 , A61P35/00 , A61K9/00
Abstract: Provided herein are methods of treating cancer in a patient comprising administering a total daily dose of 240 mg sotorasib to the patient, wherein the cancer is a KRAS G12C mutated cancer. Also provided herein are methods of treating KRAS G12C mutated cancer in a patient comprising administering a total daily dose of 960 mg sotorasib to the patient, and reducing the total daily dose of sotorasib to 480 mg in a patient experiencing an adverse event to the 960 mg dose of sotorasib.
-
公开(公告)号：US20240261289A1
公开(公告)日：2024-08-08
申请号：US18562107
申请日：2022-05-17
Applicant: AMGEN INC.
Inventor： Haby HENARY , Gataree NGARMCHAMNANRITH , Joseph PARK , Sandeep DUTTA , Gregory FRIBERG , Brett E. HOUK , Omar MATHER
IPC: A61K31/519 , A61K45/06 , A61P35/00
CPC classification number: A61K31/519 , A61K45/06 , A61P35/00
Abstract: Provided herein are methods of treating a cancer comprising a KRAS G12C mutation in a patient with active brain metastases, comprising administering sotorasib to the patient in amount effective to treat the cancer.
-
Patent Agency Ranking
公开(公告)号：US20240139193A1
公开(公告)日：2024-05-02
申请号：US17769251
申请日：2020-10-14
Applicant: AMGEN INC.
Inventor： Haby HENARY , James Russell LIPFORD
IPC: A61K31/519 , A61K31/497 , A61P35/00
CPC classification number: A61K31/519 , A61K31/497 , A61P35/00
Abstract: Provided herein are methods of administering a KRAS G12C inhibitor in combination with a SHP2 inhibitor to a cancer subject.
-
公开(公告)号：US20220378787A1
公开(公告)日：2022-12-01
申请号：US17871178
申请日：2022-07-22
Applicant: Amgen Inc.
Inventor： Haby HENARY , James Russell LIPFORD , VIctor J. CEE
IPC: A61K31/505 , A61P35/00
Abstract: Provided herein are methods of administering a KRAS G12C inhibitor to a cancer subject.
-
公开(公告)号：US20250127782A1
公开(公告)日：2025-04-24
申请号：US18689716
申请日：2022-09-07
Applicant: AMGEN INC.
Inventor： Emily CHAN , Gregory FRIBERG , Omar Ali MATHER , Brett E. HOUK , Gataree NGARMCHAMNANRITH , Haby HENARY , Sandeep DUTTA
IPC: A61K31/519 , A61K31/4745 , A61K39/395 , A61K45/06 , A61P35/00
Abstract: Provided herein are methods of treating cancer comprising a KRAS G12C mutation in a patient comprising administering to the patient sotorasib and an anti-epidermal growth factor receptor (EGFR) antibody in amounts effective to treat the cancer. Further provided herein are methods further comprising administering FOLFIRI (irinotecan, 5-FU and leucovorin) to the patient.
-
公开(公告)号：US20240082251A1
公开(公告)日：2024-03-14
申请号：US18503009
申请日：2023-11-06
Applicant: AMGEN INC.
Inventor： Haby HENARY , James Russell LIPFORD , Victor J. CEE
IPC: A61K31/519 , A61K31/53 , A61K31/5375 , A61P35/00
CPC classification number: A61K31/519 , A61K31/53 , A61K31/5375 , A61P35/00
Abstract: Provided herein are methods of administering a KRAS G12C inhibitor to a cancer subject.
-
公开(公告)号：US20230028414A1
公开(公告)日：2023-01-26
申请号：US17785852
申请日：2020-12-15
Applicant: AMGEN INC.
Inventor： Haby HENARY , James Russell LIPFORD , Victor J. CEE
IPC: A61K31/519 , A61K31/5375 , A61K31/53 , A61P35/00
Abstract: Provided herein are methods of administering a KRAS G12C inhibitor to a cancer subject.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.015 seconds)
